Denali Therapeutics (DNLI) CMO details 170,612-share equity stake in Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Denali Therapeutics Inc. Chief Medical Officer Peter Scott Chin filed an initial ownership report showing direct holdings of 170,612 shares of common stock, including 2,326 shares acquired under the Denali ESPP and 145,845 unvested RSUs. He also holds multiple fully vested or time-vesting stock options to buy common shares at exercise prices ranging from $20.17 to $80.03, with expirations extending through 2036. These positions reflect equity-based compensation typical for a senior executive and do not represent new market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Chin Peter Scott
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 43,000 shares (Direct, null);
Common Stock — 170,612 shares (Direct, null)
Footnotes (1)
- Includes 2,326 shares acquired under the Denali ESPP. Includes 145,845 Unvested RSU's. The shares subject to the option are fully vested and exercisable. 25% of the shares subject to the option vested on January 3, 2024 and an additional 1/48 of the shares vested monthly thereafter. 25% of the shares subject to the option vested on January 3, 2025 and an additional 1/48 of the shares vest monthly thereafter. 25% of the shares subject to the option vested on January 3, 2026 and an additional 1/48 of the shares vest monthly thereafter. 25% of the shares subject to the option will vest on January 3, 2027 and an additional 1/48 of the shares vest monthly thereafter.
Key Figures
Common shares held: 170,612 shares
ESPP shares included: 2,326 shares
Unvested RSUs: 145,845 units
+4 more
7 metrics
Common shares held
170,612 shares
Direct common stock holdings reported on Form 3
ESPP shares included
2,326 shares
Shares acquired under the Denali ESPP
Unvested RSUs
145,845 units
Unvested restricted stock units held by the CMO
Option block 1
63,800 shares at $20.17
Stock option exercise price and size, expires 2036-03-20
Option block 2
40,650 shares at $21.26
Stock option exercise price and size, expires 2035-01-03
Highest option strike
$80.03 per share
Exercise price on 14,250 underlying shares, expires 2031-01-10
Latest option expiry
2036-03-20
Final expiration date among reported stock options
Key Terms
Denali ESPP, Unvested RSU's, Stock Option (right to buy), fully vested and exercisable, +1 more
5 terms
Denali ESPP financial
"Includes 2,326 shares acquired under the Denali ESPP."
Unvested RSU's financial
"Includes 145,845 Unvested RSU's."
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
fully vested and exercisable financial
"The shares subject to the option are fully vested and exercisable."
vest monthly thereafter financial
"an additional 1/48 of the shares vest monthly thereafter."
FAQ
What does the Form 3 by Denali Therapeutics (DNLI) CMO report?
The Form 3 shows Chief Medical Officer Peter Scott Chin’s existing equity stake, including 170,612 common shares, unvested RSUs, and several stock option grants. It is an initial ownership statement, not a report of new share purchases or sales.
What unvested RSUs does the Denali Therapeutics (DNLI) CMO report?
The filing states that Peter Scott Chin holds 145,845 unvested RSUs. These restricted stock units generally convert into common shares over time, subject to vesting schedules tied to continued employment and, in some cases, performance conditions set by the company.
What stock options are reported by the Denali Therapeutics (DNLI) CMO?
The CMO reports several stock options to buy Denali common stock, including options over 63,800 shares at $20.17 and 40,650 shares at $21.26, with expirations between 2029 and 2036. These options form a key part of his long-term incentives.
Are the Denali Therapeutics (DNLI) CMO’s options currently exercisable?
One option block is described as fully vested and exercisable, while others vest over time. Several options vest 25% on specific January dates, with the remaining shares vesting in 1/48 monthly installments, creating a gradual, long-term vesting profile.
Does this Denali Therapeutics (DNLI) Form 3 indicate insider buying or selling?
No, this Form 3 is an initial statement of beneficial ownership. It lists existing holdings in common shares, RSUs, and options for the CMO. It does not report open-market buy or sell transactions in Denali Therapeutics stock.